PRX-119

About Protalix BioTherapeutics

Protalix BioTherapeutics leverages its unique plant cell culture platform, ProCellEx®, to develop recombinant proteins with potential advantages in cost, scalability, and safety. Its flagship product, Elelyso®, is an FDA-approved treatment for Gaucher disease, providing a validated commercial foundation. The company is actively expanding its pipeline, with promising candidates like pegunigalsidase alfa (PRX-102) for Fabry disease in late-stage development, and is exploring strategic partnerships to maximize the platform's potential across multiple therapeutic areas.

Therapeutic Areas